Blue Trust’s Cerevel Therapeutics Holdings CERE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-126
Closed -$5.15K – 3082
2024
Q3
$5.15K Buy
126
+7
+6% +$297 ﹤0.01% 2393
2024
Q2
$5.03K Buy
119
+23
+24% +$958 ﹤0.01% 2202
2024
Q1
$4.06K Sell
96
-37
-28% -$1.55K ﹤0.01% 1676
2023
Q4
$3K Buy
+133
New +$3.82K ﹤0.01% 2073
2023
Q2
– Sell
-7
Closed – – 2626
2023
Q1
$0 Buy
+7
New +$205 ﹤0.01% 2702

Blue Trust's CERE Position: Q4 2024 in Review

Blue Trust sold out of Cerevel Therapeutics Holdings (CERE) in Q4 2024, closing a stake of 126 shares — an estimated $5.15K sold.

Blue Trust first reported a position in CERE in Q1 2023 and held it in 5 quarters. The position peaked at $5.15K in Q3 2024. 0 funds tracked by Wall St. Rank hold CERE as of Q4 2024.

  • Blue Trust reported no remaining Cerevel Therapeutics Holdings position as of Q4 2024 after selling out during the quarter.
  • Blue Trust sold 126 Cerevel Therapeutics Holdings shares in Q4 2024, an estimated $5.15K.
  • Blue Trust first reported a position in Cerevel Therapeutics Holdings in Q1 2023 and held it in 5 quarters.
  • Blue Trust's Cerevel Therapeutics Holdings position peaked at $5.15K in Q3 2024.
  • 0 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings as of Q4 2024.

Based on Blue Trust's 13F filing for Q4 2024, filed 22 Jan 2025.